MEXOCELL is dedicated to advancing precision medicine and cell technology innovation, specializing in circulating tumor cell (CTC) and immune cell detection technologies. Through our proprietary R&D platform, we deliver highly accurate and real-time solutions for disease risk assessment and treatment monitoring. By participating in Proficiency Testing by the College of American Pathologists (CAP) and aligning our laboratory quality practices with the requirements of the Taiwan Accreditation Foundation (TAF) ISO/IEC 17025, we strive to ensure that our testing quality meets rigorous international standards.
Leveraging our patented cell analysis platform technology and standardized testing workflows, we deeply analyze individual immune profiles, tumor characteristics, and drug responses to assist partner medical teams in formulating more precise treatment strategies. By providing actionable reference data for clinical decisions, we connect disease monitoring, efficacy evaluation, preventive medicine, and health management—building a comprehensive precision healthcare ecosystem.
With professional expertise and high-quality services, MEXOCELL empowers clients and clinicians to identify optimal treatment directions and medical strategies. We believe that the future of healthcare extends beyond treating disease—it lies in leveraging cellular-level insights to enable early prediction, precise intervention, and continuous health tracking.
Since inception, MEXOCELL has been committed to providing the most reliable solutions, focusing relentlessly on technological breakthroughs and continuous quality enhancement.
Following our intellectual property deployment in the U.S., the team officially submitted a core technology patent application to the Intellectual Property Office, Ministry of Economic Affairs (MOEA) in Taiwan in May 2026. This milestone further consolidates MEXOCELL's technological leadership and commercial moat across Taiwan and the broader Asia-Pacific biomedical market.
To provide clients with the most credible and highest-quality testing services, MEXOCELL has officially initiated the accreditation process for Taiwan Accreditation Foundation (TAF) ISO/IEC 17025 General Requirements for the Competence of Testing Laboratories. We adhere to international standards in building a rigorous quality management system, ensuring every test result delivers international traceability and uncompromising accuracy.
Bringing together top-tier biomedical R&D talent and an experienced operational core team, MEXOCELL Biopharmaceutical Co., Ltd. officially launched on February 23, 2026. Powered by our proprietary cell culture technology, we are dedicated to translating cutting-edge academic achievements into clinical commercial solutions, opening a new chapter in next-generation precision medicine.
To safeguard the novelty of our core technology, the team officially submitted a patent application to the United States Patent and Trademark Office (USPTO) in January. This marks MEXOCELL's first step into the global market, establishing technological exclusivity at the world's highest standard.
Our R&D team achieved a monumental milestone in cell culture! We not only overcame the long-standing challenge of in vitro expansion for conventional circulating tumor cells (CTCs), but also breached a universally recognized academic hurdle by successfully expanding and co-culturing blood-derived CTCs and circulating hybrid cells (CHCs) simultaneously for the first time—unlocking revolutionary possibilities for precision oncology and drug screening.